{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/13732"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/13732","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"A murine model of glucocorticoid myopathy alleviation using androgen therapy","abstract":"Glucocorticoids (GC) are used widely for the treatment of a large number of inflammatory conditions. A loss in muscle mass and increases in muscle weakness are common complications of GC therapy. Androgen therapy has been suggested to reverse GC-associated muscle loss (GAML), but evidence of its effectiveness is inconsistent. Herein, I established a mouse model of GAML. Young adult male mice receiving 10 mg/(kg day) of the GC dexamethasone (Dexa) s.c. daily, for a week, lost 3% of their total body weight. Based on NMR lean body mass quantification and muscle dissection, more than 10% of their muscle mass was lost. More than half of the Dexa-induced muscle loss could be reversed by co-administration of 35 mg/(kg day) of testosterone (Testo). To my knowledge, this is the first mouse model of GAML demonstrating alleviation by Testo. Dexa-upregulated intramuscular atrogene expression and proteasome catalytic activity were suppressed by Testo co-administration. Dexa downregulated cathepsin L enzymatic activity and beclin expression, indicating that lysosome was not a major effector of GAML. Changes in calpain 1 and in translation factors 4E-BP, eIF3f and eIF2, following Testo treatment, were inconclusive. The changes in proteasome activity and atrogene expression were correlated with changes in expression of Foxo 1, 3a, and 4. Pro-catabolic factors REDD1 and Klf15 were repressed by Testo co-administration. C2C12 differentiated myotubes were used to model GAML in vitro. Myotube diameter and total protein were reduced by Dexa, and restored by Testo co-administration. Changes in C2C12 total protein were correlated with changes in protein degradation. Dexa-induced proteolysis was inhibited by the proteasome inhibitor MG132. In vivo, Dexa reduced intramuscular IGF-I expression, an effect reversed by Testo co-administration. In C2C12, inhibition of IGF-1R signaling with picropodophyllin did not modify Testo protective effect. Mechanisms potentially explaining these observations are discussed. In summary, my model demonstrates that Testo protective effect in GAML is mainly anti-catabolic, through the reversal of proteasome upregulation induced by Dexa. In vivo, Testo stimulates a potentially protective intramuscular IGF-I response. The roles of protein synthesis and IGF-I in anabolic myoprotection could not be addressed in these models, and require further investigations.","abstract_html":"Glucocorticoids (GC) are used widely for the treatment of a large number of inflammatory conditions. A loss in muscle mass and increases in muscle weakness are common complications of GC therapy. Androgen therapy has been suggested to reverse GC-associated muscle loss (GAML), but evidence of its effectiveness is inconsistent. Herein, I established a mouse model of GAML. Young adult male mice receiving 10 mg/(kg day) of the GC dexamethasone (Dexa) s.c. daily, for a week, lost 3% of their total body weight. Based on NMR lean body mass quantification and muscle dissection, more than 10% of their muscle mass was lost. More than half of the Dexa-induced muscle loss could be reversed by co-administration of 35 mg/(kg day) of testosterone (Testo). To my knowledge, this is the first mouse model of GAML demonstrating alleviation by Testo. Dexa-upregulated intramuscular atrogene expression and proteasome catalytic activity were suppressed by Testo co-administration. Dexa downregulated cathepsin L enzymatic activity and beclin expression, indicating that lysosome was not a major effector of GAML. Changes in calpain 1 and in translation factors 4E-BP, eIF3f and eIF2, following Testo treatment, were inconclusive. The changes in proteasome activity and atrogene expression were correlated with changes in expression of Foxo 1, 3a, and 4. Pro-catabolic factors REDD1 and Klf15 were repressed by Testo co-administration. C2C12 differentiated myotubes were used to model GAML in vitro. Myotube diameter and total protein were reduced by Dexa, and restored by Testo co-administration. Changes in C2C12 total protein were correlated with changes in protein degradation. Dexa-induced proteolysis was inhibited by the proteasome inhibitor MG132. In vivo, Dexa reduced intramuscular IGF-I expression, an effect reversed by Testo co-administration. In C2C12, inhibition of IGF-1R signaling with picropodophyllin did not modify Testo protective effect. Mechanisms potentially explaining these observations are discussed. In summary, my model demonstrates that Testo protective effect in GAML is mainly anti-catabolic, through the reversal of proteasome upregulation induced by Dexa. In vivo, Testo stimulates a potentially protective intramuscular IGF-I response. The roles of protein synthesis and IGF-I in anabolic myoprotection could not be addressed in these models, and require further investigations.","abstract_has_math":false,"creators":["Sandor, Nicolae Lucian"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Molecular Medicine","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015","date_published":"2015","updated_at":"2026-11-18T20:08:42Z","subjects":["Molecular biology"],"languages":["en_US"],"rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/13732","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/13732","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F13732","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Sandor, Nicolae Lucian"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2016-01-07T19:57:16Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2016-01-07T19:57:16Z"]},{"key":"dc:date.issued","label":"Date","values":["2015"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2015-11-03T13:16:11Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Molecular biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial-NoDerivatives 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/13732"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glucocorticoids (GC) are used widely for the treatment of a large number of inflammatory conditions. A loss in muscle mass and increases in muscle weakness are common complications of GC therapy. Androgen therapy has been suggested to reverse GC-associated muscle loss (GAML), but evidence of its effectiveness is inconsistent. Herein, I established a mouse model of GAML. Young adult male mice receiving 10 mg/(kg day) of the GC dexamethasone (Dexa) s.c. daily, for a week, lost 3% of their total body weight. Based on NMR lean body mass quantification and muscle dissection, more than 10% of their muscle mass was lost. More than half of the Dexa-induced muscle loss could be reversed by co-administration of 35 mg/(kg day) of testosterone (Testo). To my knowledge, this is the first mouse model of GAML demonstrating alleviation by Testo. Dexa-upregulated intramuscular atrogene expression and proteasome catalytic activity were suppressed by Testo co-administration. Dexa downregulated cathepsin L enzymatic activity and beclin expression, indicating that lysosome was not a major effector of GAML. Changes in calpain 1 and in translation factors 4E-BP, eIF3f and eIF2, following Testo treatment, were inconclusive. The changes in proteasome activity and atrogene expression were correlated with changes in expression of Foxo 1, 3a, and 4. Pro-catabolic factors REDD1 and Klf15 were repressed by Testo co-administration. C2C12 differentiated myotubes were used to model GAML in vitro. Myotube diameter and total protein were reduced by Dexa, and restored by Testo co-administration. Changes in C2C12 total protein were correlated with changes in protein degradation. Dexa-induced proteolysis was inhibited by the proteasome inhibitor MG132. In vivo, Dexa reduced intramuscular IGF-I expression, an effect reversed by Testo co-administration. In C2C12, inhibition of IGF-1R signaling with picropodophyllin did not modify Testo protective effect. Mechanisms potentially explaining these observations are discussed. In summary, my model demonstrates that Testo protective effect in GAML is mainly anti-catabolic, through the reversal of proteasome upregulation induced by Dexa. In vivo, Testo stimulates a potentially protective intramuscular IGF-I response. The roles of protein synthesis and IGF-I in anabolic myoprotection could not be addressed in these models, and require further investigations."]},{"key":"dc:title","label":"Title","values":["A murine model of glucocorticoid myopathy alleviation using androgen therapy"]}]}],"canonical_facts":{"dc:creator":["Sandor, Nicolae Lucian"],"dc:date.accessioned":["2016-01-07T19:57:16Z"],"dc:date.available":["2016-01-07T19:57:16Z"],"dc:date.issued":["2015"],"dc:date.updated":["2015-11-03T13:16:11Z"],"dc:description.abstract":["Glucocorticoids (GC) are used widely for the treatment of a large number of inflammatory conditions. A loss in muscle mass and increases in muscle weakness are common complications of GC therapy. Androgen therapy has been suggested to reverse GC-associated muscle loss (GAML), but evidence of its effectiveness is inconsistent. Herein, I established a mouse model of GAML. Young adult male mice receiving 10 mg/(kg day) of the GC dexamethasone (Dexa) s.c. daily, for a week, lost 3% of their total body weight. Based on NMR lean body mass quantification and muscle dissection, more than 10% of their muscle mass was lost. More than half of the Dexa-induced muscle loss could be reversed by co-administration of 35 mg/(kg day) of testosterone (Testo). To my knowledge, this is the first mouse model of GAML demonstrating alleviation by Testo. Dexa-upregulated intramuscular atrogene expression and proteasome catalytic activity were suppressed by Testo co-administration. Dexa downregulated cathepsin L enzymatic activity and beclin expression, indicating that lysosome was not a major effector of GAML. Changes in calpain 1 and in translation factors 4E-BP, eIF3f and eIF2, following Testo treatment, were inconclusive. The changes in proteasome activity and atrogene expression were correlated with changes in expression of Foxo 1, 3a, and 4. Pro-catabolic factors REDD1 and Klf15 were repressed by Testo co-administration. C2C12 differentiated myotubes were used to model GAML in vitro. Myotube diameter and total protein were reduced by Dexa, and restored by Testo co-administration. Changes in C2C12 total protein were correlated with changes in protein degradation. Dexa-induced proteolysis was inhibited by the proteasome inhibitor MG132. In vivo, Dexa reduced intramuscular IGF-I expression, an effect reversed by Testo co-administration. In C2C12, inhibition of IGF-1R signaling with picropodophyllin did not modify Testo protective effect. Mechanisms potentially explaining these observations are discussed. In summary, my model demonstrates that Testo protective effect in GAML is mainly anti-catabolic, through the reversal of proteasome upregulation induced by Dexa. In vivo, Testo stimulates a potentially protective intramuscular IGF-I response. The roles of protein synthesis and IGF-I in anabolic myoprotection could not be addressed in these models, and require further investigations."],"dc:identifier.uri":["https://hdl.handle.net/2144/13732"],"dc:language.iso":["en_US"],"dc:rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["Molecular biology"],"dc:title":["A murine model of glucocorticoid myopathy alleviation using androgen therapy"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Molecular Medicine"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:08:42Z"}